Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov
Abstract Novel biologics in MG therapy research is on the rise. This research aimed to investigate the characteristics of registered trials on novel therapies for myasthenia gravis on ClinicalTrials.gov. This cross-sectional study used a descriptive approach to assess the features of the included tr...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-01-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-024-52539-w |
| _version_ | 1797276580067672064 |
|---|---|
| author | Xingyue Li Jinxin Chen Youtao Wang Siwei Zheng Kun Wan Xiaodong Liu |
| author_facet | Xingyue Li Jinxin Chen Youtao Wang Siwei Zheng Kun Wan Xiaodong Liu |
| author_sort | Xingyue Li |
| collection | DOAJ |
| description | Abstract Novel biologics in MG therapy research is on the rise. This research aimed to investigate the characteristics of registered trials on novel therapies for myasthenia gravis on ClinicalTrials.gov. This cross-sectional study used a descriptive approach to assess the features of the included trials on ClinicalTrials.gov. We found 62 registered trials from 2007 to 2023 on ClinicalTrials.gov. The results showed a yearly rise in the number of registered trials (r = 0.76, p < 0.001). Following 2017, more industry-sponsored trials were conducted (91.5% [43] vs. 60% [9], p = 0.009), fewer results were released (10.6% [5] vs. 60% [9], p = 0.001), and more trials entered phase 3 (67.4% [31] vs. 20% [2], p = 0.001). The most researched novel medications were neonatal Fc receptor inhibitors (51.2% [21]), complement inhibitors (39.0% [16]), and B cell depletors (14.6% [6]). According to the website’s data, the neonatal Fc receptor inhibitors and complement inhibitors were effective in treating myasthenia gravis patients in three trials (NCT03315130, NCT03669588, and NCT00727194). This study provides valuable insights into the profile of registered trials on novel therapies for myasthenia gravis. More clinical studies are needed in the future to prove the value of its application. |
| first_indexed | 2024-03-07T15:30:14Z |
| format | Article |
| id | doaj.art-f2b8adc9ba3a4557a16dbbd902f1aa8d |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-07T15:30:14Z |
| publishDate | 2024-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-f2b8adc9ba3a4557a16dbbd902f1aa8d2024-03-05T16:28:40ZengNature PortfolioScientific Reports2045-23222024-01-011411910.1038/s41598-024-52539-wRegistered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.govXingyue Li0Jinxin Chen1Youtao Wang2Siwei Zheng3Kun Wan4Xiaodong Liu5Department of Neurology, Xiangyang No.1 People’s Hospital, Hubei University of MedicineHubei University of MedicineHubei University of MedicineHubei University of MedicineHubei University of MedicineDepartment of Neurology, Taihe Hospital, Hubei University of MedicineAbstract Novel biologics in MG therapy research is on the rise. This research aimed to investigate the characteristics of registered trials on novel therapies for myasthenia gravis on ClinicalTrials.gov. This cross-sectional study used a descriptive approach to assess the features of the included trials on ClinicalTrials.gov. We found 62 registered trials from 2007 to 2023 on ClinicalTrials.gov. The results showed a yearly rise in the number of registered trials (r = 0.76, p < 0.001). Following 2017, more industry-sponsored trials were conducted (91.5% [43] vs. 60% [9], p = 0.009), fewer results were released (10.6% [5] vs. 60% [9], p = 0.001), and more trials entered phase 3 (67.4% [31] vs. 20% [2], p = 0.001). The most researched novel medications were neonatal Fc receptor inhibitors (51.2% [21]), complement inhibitors (39.0% [16]), and B cell depletors (14.6% [6]). According to the website’s data, the neonatal Fc receptor inhibitors and complement inhibitors were effective in treating myasthenia gravis patients in three trials (NCT03315130, NCT03669588, and NCT00727194). This study provides valuable insights into the profile of registered trials on novel therapies for myasthenia gravis. More clinical studies are needed in the future to prove the value of its application.https://doi.org/10.1038/s41598-024-52539-w |
| spellingShingle | Xingyue Li Jinxin Chen Youtao Wang Siwei Zheng Kun Wan Xiaodong Liu Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov Scientific Reports |
| title | Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov |
| title_full | Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov |
| title_fullStr | Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov |
| title_full_unstemmed | Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov |
| title_short | Registered trials on novel therapies for myasthenia gravis: a cross-sectional study on ClinicalTrials.gov |
| title_sort | registered trials on novel therapies for myasthenia gravis a cross sectional study on clinicaltrials gov |
| url | https://doi.org/10.1038/s41598-024-52539-w |
| work_keys_str_mv | AT xingyueli registeredtrialsonnoveltherapiesformyastheniagravisacrosssectionalstudyonclinicaltrialsgov AT jinxinchen registeredtrialsonnoveltherapiesformyastheniagravisacrosssectionalstudyonclinicaltrialsgov AT youtaowang registeredtrialsonnoveltherapiesformyastheniagravisacrosssectionalstudyonclinicaltrialsgov AT siweizheng registeredtrialsonnoveltherapiesformyastheniagravisacrosssectionalstudyonclinicaltrialsgov AT kunwan registeredtrialsonnoveltherapiesformyastheniagravisacrosssectionalstudyonclinicaltrialsgov AT xiaodongliu registeredtrialsonnoveltherapiesformyastheniagravisacrosssectionalstudyonclinicaltrialsgov |